GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Spermosens AB (XSAT:SPERM) » Definitions » Cash Flow from Financing

Spermosens AB (XSAT:SPERM) Cash Flow from Financing : kr15.37 Mil (TTM As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Spermosens AB Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2025, Spermosens AB paid kr0.00 Mil more to buy back shares than it received from issuing new shares. It received kr0.00 Mil from issuing more debt. It paid kr0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received kr0.00 Mil from paying cash dividends to shareholders. It received kr0.00 Mil on other financial activities. In all, Spermosens AB spent kr0.00 Mil on financial activities for the three months ended in Mar. 2025.


Spermosens AB Cash Flow from Financing Historical Data

The historical data trend for Spermosens AB's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spermosens AB Cash Flow from Financing Chart

Spermosens AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Financing
Get a 7-Day Free Trial 8.34 21.63 19.39 27.14 8.53

Spermosens AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.84 9.36 -0.15 2.39 3.77

Spermosens AB Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Spermosens AB's Cash from Financing for the fiscal year that ended in Dec. 2024 is calculated as:

Spermosens AB's Cash from Financing for the quarter that ended in Mar. 2025 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr15.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Spermosens AB  (XSAT:SPERM) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Spermosens AB's issuance of stock for the three months ended in Mar. 2025 was kr0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Spermosens AB's repurchase of stock for the three months ended in Mar. 2025 was kr0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Spermosens AB's net issuance of debt for the three months ended in Mar. 2025 was kr0.00 Mil. Spermosens AB received kr0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Spermosens AB's net issuance of preferred for the three months ended in Mar. 2025 was kr0.00 Mil. Spermosens AB paid kr0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Spermosens AB's cash flow for dividends for the three months ended in Mar. 2025 was kr0.00 Mil. Spermosens AB received kr0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Spermosens AB's other financing for the three months ended in Mar. 2025 was kr0.00 Mil. Spermosens AB received kr0.00 Mil on other financial activities.


Spermosens AB Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Spermosens AB's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Spermosens AB Business Description

Traded in Other Exchanges
Address
Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Spermosens AB is developing a revolutionary platform technology for diagnosing male-factor infertility and directing to the right infertility treatment. It is a developer of medical device products for male infertility, individualizing In Vitro Fertilization (IVF) diagnostics and treatment creating a new standard for faster and safer IVF treatments.

Spermosens AB Headlines

No Headlines